

## Special Issue

# Review Special Issue Series— Measuring Neutralizing Antibody Responses Against SARS-CoV-2 and Emerging Infectious Diseases

### Message from the Guest Editor

Dear Colleagues As the guest editor, I am pleased to announce the Special Issue “Measuring Neutralizing Antibody Responses against SARS-CoV-2 and Emerging Infectious Diseases”, in which we aim to encourage more submissions of review papers. Please note the following instructions:

- The word count should be more than 3000 words in the main text;
- Manuscripts must cite the newest published research;
- Manuscripts must comprehensively summarize the current hot topics.

*Vaccines* will provide full support for long reviews (5000 or more words in the main text) of high quality. For more detailed information, please do not hesitate to contact the *Vaccines* Office: [vaccines@mdpi.com](mailto:vaccines@mdpi.com).

---

### Guest Editor

Dr. Ruth Harvey  
The Francis Crick Institute, London, UK

---

### Deadline for manuscript submissions

closed (31 May 2025)



## Vaccines

---

an Open Access Journal  
by MDPI

---

**Impact Factor 3.4**  
**CiteScore 9.9**  
**Indexed in PubMed**



[mdpi.com/si/153220](https://mdpi.com/si/153220)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,  
University of Georgia, Athens, GA 30602-7387, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).